• Skip to main content

UltimateKratom.com

UltimateKratom.com | Ultimate Kratom Reviews

  • Kratom Strains
  • Safety & Law
  • Buying Guide
  • Wellness
  • About

Nov 19 2026

Kratom Research Evidence: Studies, Limits, and Questions

Kratom research is real, but human research is still limited. Studies can explain what people report, how kratom compounds act in laboratory work, and which safety questions need closer study. They cannot yet tell you that kratom is safe or effective for a medical purpose, or predict what one product will do for you.

Kratom means both the Southeast Asian tree Mitragyna speciosa and products made from its leaves. Its long history in Thailand and neighboring countries helps explain why people study it, while modern research is still sorting out leaf products, isolated compounds, and more concentrated formulations.

What kinds of kratom research are there?

A useful way to read kratom research is to first identify what kind of question the study can answer. A study of cells or animals can explore a possible biological mechanism. A survey can describe what respondents say they use and experience. A case report can document a clinical event. A controlled human study can compare a defined product or compound under planned conditions.

Study typeWhat it can help answerWhat it cannot settle
Laboratory or animal researchHow a compound may act and which questions deserve human studyHow a retail kratom product will affect people
SurveyWho responded, why they said they used kratom, and patterns they reportedWhether kratom caused a reported outcome
Case reportWhat happened in one clinical situation and what clinicians should investigateHow common an event is or what caused it by itself
Controlled human studyWhat a defined intervention does in the people and timeframe studiedWhether the result applies to every formulation or person

This plain-language taxonomy matters because the word “study” can make very different evidence sound interchangeable. For a closer explanation of how study designs affect confidence, see evidence quality (our research library).

Are there clinical trials of kratom?

There are few published reports from well-designed human studies in which kratom was administered to people, according to the FDA. The agency says it funded a single-ascending-dose study of botanical kratom and that a human abuse-potential study received funding in September 2024; results still need to be considered alongside the many different products sold to consumers.

The short answer

Kratom research is real, but human research is still limited.

There is also an important distinction between whole-plant kratom and an isolated compound. On June 1, 2026, NIH announced that an Investigational New Drug application for a purified mitragynine formulation had taken effect, allowing an NIH-led phase I trial to begin. NIH described that planned trial as the first randomized, double-blind, placebo-controlled human study of that formulation’s safety and tolerability. That is a study of a purified formulation, not a finding about every kratom leaf, powder, extract, or other product.

What do surveys and interviews show?

Surveys are useful for understanding why respondents say they use kratom and what their use patterns look like. A 2020 anonymous online survey summarized by Johns Hopkins included 2,798 respondents and described their self-reported demographics, use patterns, and perceived effects. It is useful context about the respondents; it is not a clinical trial or proof of a health outcome.

A separate Johns Hopkins analysis combining an online convenience sample with 2019 National Survey on Drug Use and Health data found that nonmedical opioid-use history was associated with a greater likelihood of past-year kratom use. That association describes a pattern in the studied data; it does not tell you why any one person uses kratom or what result they will have.

Small qualitative studies add personal detail. One published narrative interview series involved 10 adults who used kratom regularly. Participants described their experiences, including perceived effects and tolerance. The authors themselves noted that controlled human studies of kratom alkaloids are needed. Interviews can help researchers ask better next questions, but they cannot establish a benefit, a typical effect, or a recovery timeline.

Is kratom an opioid?

Kratom is not listed in the U.S. schedule of controlled substances, according to the National Center for Complementary and Integrative Health. But mitragynine and 7-hydroxymitragynine interact with opioid receptors in the brain. That receptor activity is why studies often compare parts of kratom’s pharmacology with opioids, while also examining other mechanisms and the differences among compounds.

Quick answer

Is kratom an opioid? Kratom is not listed in the U.S. schedule of controlled substances, according to the National Center for Complementary and Integrative Health.

Do not treat “kratom” as one identical research subject. The FDA says natural kratom leaves contain 7-hydroxymitragynine, or 7-OH, as a minor constituent, while products can vary substantially. Research on a purified compound or a concentrated formulation does not automatically apply to botanical leaf material. For the broader product-and-safety context, see current research and safety.

How should you read a kratom study?

Start with four practical questions:

  • What exactly was studied? Look for botanical leaf, a defined extract, an isolated compound, or self-reported use of products with varying contents.
  • Who was studied? A finding from a selected group of survey respondents may not apply to the wider public.
  • What was compared? A controlled comparison answers a different question than an interview, case report, or laboratory experiment.
  • What was measured and for how long? A short-term observation cannot answer a long-term question, and a reported experience is not the same as a medical outcome.

Then check whether the conclusion stays inside those boundaries. This is especially important when an ad turns a laboratory finding, a survey response, or a traditional use into a promise about a product.

What do laboratory studies tell us?

Laboratory research has helped identify mitragynine and 7-OH as widely studied kratom-related compounds and has examined how they interact with receptors. NIDA says mitragynine, 7-OH, and other compounds are being studied for complex pharmacological and behavioral effects. That work is a starting point for research, not a substitute for human evidence on a retail product.

Quick answer

What do laboratory studies tell us? Laboratory research has helped identify mitragynine and 7-OH as widely studied kratom-related compounds and has examined how they interact with receptors.

NIH reported preclinical findings in animal models before its planned phase I mitragynine study. Preclinical research can support the decision to investigate a compound in people. It cannot establish that the compound is safe or effective in people before the human study is completed.

What remains unknown about kratom?

The major unknowns are not minor details. NCCIH says very little research in people has evaluated kratom’s health effects, and that short- and long-term effects, safety, and possible therapeutic uses still need study. NIDA likewise says researchers are still learning about chemical compounds, long-term health effects, interactions with other substances, and the differences among products.

That means current research cannot answer how long a person’s brain will take to recover after kratom use, whether daily use will lead to a particular outcome, whether kratom changes appearance or eye health, or whether it provides a health benefit for women, men, or any other group. It also cannot turn a color name such as “green” into a research-backed outcome. These are questions that require a defined product, a defined population, and well-designed human research.

What can the evidence not tell you about toxicology reports?

A toxicology result depends on the test method, what analytes a laboratory includes, the specimen, and the purpose of the test. If that question affects work, care, or a legal matter, ask the testing program or laboratory which analytes and confirmation methods its report covers.

What do safety reports add?

Safety reports are important, but they answer a narrower question than a trial. NCCIH lists reported mild effects such as nausea, constipation, dizziness, and drowsiness, along with rare serious reports including seizures, high blood pressure, and liver problems. It also says harmful contaminants have been found in some kratom products.

Case reports and toxicology findings can flag patterns worth studying, especially when other substances or contaminants may be involved. They do not show that a particular event will happen to you or identify a safe product. If you are considering kratom while taking medication or have a health concern, bring the product identity and your questions to a qualified clinician; kratom safety research explains the interaction and dependence questions in more detail.

What is the right next step?

Use research to narrow your question, not to force a conclusion it cannot support. Write down the exact form of kratom you mean, the outcome you are trying to understand, other substances or medicines involved, and the question you want a qualified professional to answer. That makes it easier to separate a study of an isolated compound from a claim about a product, and a survey finding from an answer about your situation.

By UltimateKratom.com Research Desk

Further reading

  1. How to Read a Kratom COA

Written by UltimateKratom.com Research Desk · Categorized: botanical research

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • Editorial Policy
  • Review Process
  • Corrections
  • Contact
  • Privacy Policy
  • Terms of Use
  • Medical Disclaimer
  • Affiliate Disclosure

Copyright © 2026 · UltimateKratom.com